Litcius/Paper detail

Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13

Jianzhang Yang, Yu Chang, Jean C. Tien, Zhen Wang, Yang Zhou, Pujuan Zhang, Weixue Huang, Josh N. Vo, Ingrid J. Apel, Cynthia Wang, Victoria Zhixuan Zeng, Yunhui Cheng, Shuqin Li, George Xiaoju Wang, Arul M. Chinnaiyan, Ke Ding

2022Journal of Medicinal Chemistry74 citationsDOIOpen Access PDF

Abstract

, suggesting the potential advantage of a CDK12/13 degrader for TNBC targeted therapy.

Topics & Concepts

ChemistryCancer researchProteolysisDNA damageGrowth inhibitionKinaseIn vitroBiologyBiochemistryDNAEnzymeProtein Degradation and InhibitorsAdvanced Breast Cancer TherapiesPARP inhibition in cancer therapy
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 | Litcius